| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
115.21(B) |
| Last
Volume: |
975,365 |
Avg
Vol: |
1,608,800 |
| 52
Week Range: |
$323.62 - $456.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
23,137 |
144,475 |
259,873 |
619,971 |
| Total Sell Value |
$10,319,530 |
$60,539,246 |
$102,205,755 |
$209,876,745 |
| Total People Sold |
7 |
12 |
14 |
18 |
| Total Sell Transactions |
7 |
40 |
65 |
130 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tatsis Ourania |
SVP, CRO |
• – – |
2020-02-18 |
4 |
AS |
$241.82 |
$311,585 |
D/D |
(1,279) |
15,070 |
|
16% |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2020-02-18 |
4 |
AS |
$241.78 |
$2,845,518 |
D/D |
(11,685) |
111,541 |
|
16% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-18 |
4 |
AS |
$241.95 |
$380,957 |
D/D |
(1,564) |
16,876 |
|
16% |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-18 |
4 |
AS |
$242.04 |
$849,780 |
D/D |
(3,489) |
39,447 |
|
16% |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-18 |
4 |
AS |
$241.75 |
$762,020 |
D/D |
(3,128) |
32,282 |
|
16% |
|
| Kewalramani Reshma |
EVP and CMO |
• • – |
2020-02-17 |
4 |
D |
$241.50 |
$227,976 |
D/D |
(944) |
34,341 |
|
- |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$602,784 |
D/D |
(2,496) |
44,839 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$602,784 |
D/D |
(2,496) |
37,474 |
|
- |
|
| Tatsis Ourania |
SVP, CRO |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$144,176 |
D/D |
(597) |
16,349 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2020-02-17 |
4 |
D |
$241.50 |
$2,249,331 |
D/D |
(9,314) |
123,226 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$301,392 |
D/D |
(1,248) |
18,440 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$787,773 |
D/D |
(3,262) |
42,936 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$602,784 |
D/D |
(2,496) |
35,410 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-11 |
4 |
AS |
$243.42 |
$4,154,832 |
D/D |
(16,882) |
37,906 |
|
18% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-11 |
4 |
AS |
$243.36 |
$4,191,771 |
D/D |
(17,032) |
39,970 |
|
18% |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2020-02-11 |
4 |
AS |
$243.37 |
$11,694,933 |
D/D |
(47,523) |
132,540 |
|
18% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-11 |
4 |
AS |
$243.59 |
$1,442,301 |
D/D |
(5,862) |
19,688 |
|
18% |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-11 |
4 |
AS |
$243.53 |
$3,216,311 |
D/D |
(13,070) |
46,198 |
|
18% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-11 |
4 |
AS |
$243.76 |
$2,777,325 |
D/D |
(11,286) |
47,335 |
|
18% |
|
| Lee Yuchun |
Director |
– • – |
2020-02-10 |
4 |
AS |
$240.04 |
$286,403 |
D/D |
(1,181) |
1,875 |
|
22% |
|
| Lee Yuchun |
Director |
– • – |
2020-02-10 |
4 |
OE |
$57.27 |
$67,636 |
D/D |
1,181 |
3,056 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$3,242,705 |
D/D |
(13,458) |
54,788 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$3,206,563 |
D/D |
(13,308) |
57,002 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2020-02-10 |
4 |
D |
$240.95 |
$8,856,117 |
D/D |
(36,755) |
180,063 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$1,125,959 |
D/D |
(4,673) |
25,550 |
|
- |
|
3277 Records found
|
|
Page 26 of 132 |
|
|
1.92 (0.44%) 
